---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-005869"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:29:52.022283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M

## Summary
- Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.
- GAAP net income Q4 2025 $13.4M ($0.27 basic) vs $19.3M ($0.39) YoY; non-GAAP adjusted net income $15.1M ($0.30).
- Full year 2025 total revenue $228.4M; GAAP net income $31.1M ($0.62) vs $30.3M ($0.62) YoY.
- Cash, equivalents & marketable securities $97.5M; total debt reduced to $22.5M from $67.0M at end of 2024.
- FY2026 guidance: net product revenue $194-198M; total revenue $214-221M; net income $10-13M, excluding valuation allowance.

## SEC filing metadata
- accession: 0001437749-26-005869
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/0001437749-26-005869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/pbyi20260204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-005869
- JSON: https://secwatch.observer/filing/0001437749-26-005869.json
- Plain text: https://secwatch.observer/filing/0001437749-26-005869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.